Bartlett & CO. Wealth Management LLC Has $7.21 Million Stock Position in Bristol Myers Squibb Company $BMY

Bartlett & CO. Wealth Management LLC decreased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 155,743 shares of the biopharmaceutical company’s stock after selling 3,429 shares during the quarter. Bartlett & CO. Wealth Management LLC’s holdings in Bristol Myers Squibb were worth $7,209,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in BMY. Brighton Jones LLC raised its holdings in shares of Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the period. Baker Tilly Wealth Management LLC increased its position in Bristol Myers Squibb by 15.1% during the first quarter. Baker Tilly Wealth Management LLC now owns 6,956 shares of the biopharmaceutical company’s stock worth $424,000 after buying an additional 911 shares during the last quarter. NBC Securities Inc. increased its position in Bristol Myers Squibb by 102,110.0% during the first quarter. NBC Securities Inc. now owns 10,221 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 10,211 shares during the last quarter. Fragasso Financial Advisors Inc acquired a new position in Bristol Myers Squibb during the first quarter worth approximately $208,000. Finally, Merit Financial Group LLC boosted its stake in shares of Bristol Myers Squibb by 21.6% during the 1st quarter. Merit Financial Group LLC now owns 51,601 shares of the biopharmaceutical company’s stock worth $3,147,000 after acquiring an additional 9,166 shares during the period. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Performance

BMY opened at $45.00 on Wednesday. Bristol Myers Squibb Company has a 52-week low of $42.96 and a 52-week high of $63.33. The business’s fifty day moving average is $46.52 and its 200-day moving average is $48.86. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The firm has a market cap of $91.59 billion, a P/E ratio of 18.15, a price-to-earnings-growth ratio of 2.26 and a beta of 0.35.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. Bristol Myers Squibb’s revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.5%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.07% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts have recently commented on BMY shares. Wall Street Zen downgraded Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. Citigroup dropped their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a research report on Friday, August 1st. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective on the stock. in a research report on Tuesday, August 5th. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Finally, Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $56.38.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.